The Global HGH Biosimilars Market Report is equipped with market data from 2014 to 2024. The report gives a market overview covering key drivers and risks factors. The report is bifurcated by top global manufactures mentioning sales, revenue and prices as applicable. It also evaluates the competitive scenario of the leading players. The report expands to cover regional market data along with type and application. The report forecasts sales and revenue from 2019 to 2024. The detailed sales channel is also covered in the study.
HGH Biosimilars is DNA recombinant human growth hormone, which has the same function as human growth hormone. It can promote bone, visceral and whole body growth, promote protein synthesis, affect fat and mineral metabolism, and play a key role in human growth and development. Subcutaneous injection of about 80% was absorbed, 5 hours to reach the peak of blood drug concentration, the half-life of 4 hours. About 90% of the injection dose is metabolized in the liver. Only about 0.1% of the dose is excreted from the biliary tract and the kidneys.
Scope of the Report:
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
This report analyzes the worldwide markets for HGH Biosimilars in US$ by following Product Segments.: Clinical, Experiment and Others
Company profiles are primarily based on public domain information including company
- Johnson & Johnson
- Gilead Sciences
- Pacira
- Sun Pharmaceutical
- Luye Pharma
- Sigma-Tau Group
- Fudan-Zhangjiang
- Teva Pharmaceutical
- CSPC
- Novartis
- Kingond Pharm
The worldwide market for HGH Biosimilars is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019.
This report focuses on the HGH Biosimilars in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Johnson & Johnson
- Gilead Sciences
- Pacira
- Sun Pharmaceutical
- Luye Pharma
- Sigma-Tau Group
- Fudan-Zhangjiang
- Teva Pharmaceutical
- CSPC
- Novartis
- Kingond Pharm
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe HGH Biosimilars product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of HGH Biosimilars, with price, sales, revenue and global market share of HGH Biosimilars in 2017 and 2018.
Chapter 3, the HGH Biosimilars competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the HGH Biosimilars breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, HGH Biosimilars market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe HGH Biosimilars sales channel, distributors, customers, research findings and conclusion, appendix and data source.